How to Stop Bile Diarrhea: Causes, Diagnosis & Treatment

Bile acid diarrhea is most effectively stopped with bile acid sequestrant medications, which bind excess bile acids in the gut before they can trigger watery stools. Cholestyramine and colesevelam are the main drugs used, and roughly four out of five people with confirmed bile acid diarrhea respond to them. But stopping the symptoms is only part of the picture. Bile acid diarrhea, often abbreviated BAD, is widely underdiagnosed and frequently mistaken for irritable bowel syndrome, which means many people never get to that treatment step in the first place.

What Bile Acids Do and Why They Sometimes Cause Diarrhea

Your liver produces bile acids to help digest and absorb dietary fats. After a meal, bile acids are released into the small intestine, do their job, and then get reabsorbed near the end of the small intestine (the ileum) and shuttled back to the liver for reuse. This recycling loop runs several times per meal and is tightly regulated by a feedback system: when enough bile acids are being reabsorbed, a signaling molecule called FGF19 tells the liver to slow down production.

Problems arise when that loop breaks down. If too many bile acids escape reabsorption and spill into the colon, they provoke a cascade of effects. They push water into the colon, stimulate mucus secretion from the lining, and trigger high-amplitude contractions that speed everything toward the exit.¹ The result is urgent, watery diarrhea that can strike multiple times a day, often with cramping, bloating, and little warning.

The Three Types of Bile Acid Diarrhea

Clinicians sort BAD into three categories depending on why the bile acid recycling system has gone wrong. Understanding which type applies to you shapes treatment decisions and long-term expectations.

Type 1 follows damage to the ileum, the stretch of small intestine where bile acids are normally reabsorbed. The most common culprit is Crohn’s disease with ileal involvement or surgical removal of part of the ileum. The longer the segment removed, the worse the malabsorption tends to be.² Radiation therapy to the abdomen can also damage the ileum enough to cause this type.

Type 2 is called primary or idiopathic BAD. The ileum looks structurally normal, yet the body overproduces bile acids. Research points to a defect in the feedback loop: patients with this type tend to have significantly lower levels of FGF19, the hormone that tells the liver to ease off bile acid production.³ The liver keeps churning out bile acids that overwhelm the ileum’s capacity to reabsorb them. This is actually the most common form, and the one most often misdiagnosed as IBS.

Type 3 is a catch-all for BAD triggered by other gastrointestinal conditions or procedures where the ileum itself is not the primary problem. Gallbladder removal (cholecystectomy) is the best-known trigger. Without the gallbladder acting as a storage reservoir, bile acids flow more continuously into the intestine, disrupting the enterohepatic cycle.⁴ Other conditions occasionally linked to type 3 include diabetes, celiac disease, small intestinal bacterial overgrowth, and microscopic colitis, though those associations are less consistent.⁵

How Common Is Bile Acid Diarrhea, and Why Is It Missed So Often?

BAD is far more common than most people, and many doctors, realize. A meta-analysis pooling data from several studies found that about 28% of patients diagnosed with diarrhea-predominant IBS actually had bile acid malabsorption.⁶ A separate study using validated diagnostic criteria put the prevalence of primary BAD even higher, at about 38% among patients meeting criteria for IBS with diarrhea or functional diarrhea, with nearly half of those cases being moderate to severe.⁷

These numbers are striking. They mean that somewhere between a quarter and a third of people living with a diagnosis of IBS-D may have been given the wrong label. The core issue is that BAD symptoms, urgent watery diarrhea, cramping, bloating, overlap almost perfectly with IBS-D symptoms. Without specific bile acid testing, which many clinicians do not routinely order, the two conditions are essentially indistinguishable based on symptoms alone. A study of patients with IBS-D who were specifically tested for BAD found that those with bile acid diarrhea tended to be older and have a higher body mass index, but those differences are subtle and not reliable enough for clinical distinction.⁸

Getting Diagnosed

Testing for BAD is one of the biggest hurdles, because the best-studied diagnostic tool is not available everywhere. There are several approaches, each with trade-offs.

The SeHCAT test is widely considered the gold standard. You swallow a capsule containing a synthetic bile acid labeled with a small amount of selenium-75, and a scan measures how much is retained in your body seven days later. Low retention means your body is losing bile acids instead of recycling them. The test gives a quantitative severity score that helps predict how well you might respond to treatment.⁹ The catch? It is not approved or readily available in many countries, including the United States, which creates a diagnostic gap for millions of patients.

Where SeHCAT is unavailable, clinicians turn to blood tests and stool tests. A fasting blood level of C4, a bile acid precursor, can indicate overproduction. Similarly, low fasting levels of FGF19, the feedback hormone, suggest the regulatory loop is not working properly. Both markers have high negative predictive value, meaning they are fairly good at ruling BAD out when results are normal.¹⁰ However, neither test alone is as accurate as SeHCAT for confirming the diagnosis. The sensitivity for FGF19 at commonly used cutoffs hovers around 58% to 74%, depending on the severity threshold being tested.¹¹

A 48-hour fecal bile acid collection is another option, particularly in the U.S. Patients eat a standardized high-fat diet for several days and collect stool samples, which are then analyzed for total and primary bile acid levels. Elevated primary bile acids, elevated total bile acids, or both can confirm the diagnosis using validated cutoffs.¹² This test is thorough but burdensome for patients, requiring days of dietary preparation and stool collection.

In practice, many gastroenterologists skip formal testing entirely and use a therapeutic trial instead. They prescribe a bile acid sequestrant and see whether symptoms improve. If they do, that is treated as indirect confirmation of BAD. This approach is quick and pragmatic, though it misses the chance to classify severity and can leave patients without a firm diagnosis if the drug produces side effects that muddy the picture.

Bile Acid Sequestrants as First-Line Treatment

Cholestyramine has been the traditional first-line drug for decades. It is a powder mixed into liquid that works by binding bile acids in the gut so they pass out in stool rather than irritating the colon. A meta-analysis of patients with bile acid diarrhea after cholecystectomy found that about 79% responded to cholestyramine.¹³ That is a strong response rate for any gastrointestinal drug. The problem is tolerability. Cholestyramine tastes unpleasant, has a gritty texture, and commonly causes bloating, constipation, and nausea. Many patients start it, struggle with the side effects, and abandon it before giving it a fair chance.

Colesevelam is a newer bile acid sequestrant that comes in tablet form. It tends to cause fewer gastrointestinal side effects and is considerably easier to take.¹⁴ A double-blind, placebo-controlled trial tested colesevelam specifically in patients with confirmed BAD and found that about 59% to 64% of those on colesevelam achieved remission, compared with only 13% to 16% on placebo.¹⁵ No serious adverse events were reported in that trial. Separately, colesevelam was shown to firm up stool consistency in patients with IBS-D, with a meaningful decrease in scores on the Bristol Stool Form Scale.¹⁶

One important nuance: bile acid sequestrants can interfere with the absorption of other medications and fat-soluble vitamins. You typically need to take other pills at least an hour before or four hours after the sequestrant. Your doctor should review potential interactions, especially if you take thyroid medication, blood thinners, or certain heart drugs.

The Role of a Low-Fat Diet

Dietary fat is the main trigger for bile acid release. The more fat you eat, the more bile your liver pumps into the intestine, and the more bile acids end up in the colon if reabsorption is impaired. Reducing dietary fat can therefore lower the bile acid load reaching the colon and ease symptoms without medication, or alongside it.

Two studies on low-fat dietary intervention for patients with confirmed BAD found meaningful improvements. In one, patients prescribed a diet providing about 20% of daily energy from fat showed significant reductions in abdominal pain and nighttime bowel movements.¹⁷ In the other, reducing average daily fat intake to roughly 42 grams led to significant improvements in urgency, bloating, loss of bowel control, and frequency.¹⁸

In practical terms, a low-fat diet for BAD means cutting back on fried foods, fatty cuts of meat, full-fat dairy, pastries, and oil-heavy dressings. You do not need to eliminate fat entirely, and doing so would be nutritionally unwise. The goal is moderation. Some people find that combining a reduced-fat diet with a bile acid sequestrant gives better control than either strategy alone, though formal combination trials are limited. It is worth working with a dietitian if you are unsure how to restructure meals without losing essential nutrients.

Emerging Treatments and Investigational Drugs

For people who cannot tolerate bile acid sequestrants or do not respond adequately, the pipeline is thin but growing. The most intriguing approach targets the root cause of type 2 BAD: the broken feedback loop.

Obeticholic acid is a synthetic bile acid that activates the same receptor (FXR) responsible for triggering the feedback signal. In a proof-of-concept study, it boosted FGF19 levels and reduced bile acid production, producing clinical improvement in patients with BAD.¹⁹ A case report documented one patient with severe BAD and intestinal failure whose stool frequency dropped from about 13 to about 7 episodes per day on obeticholic acid, with the effect sustained over six months.²⁰ Obeticholic acid is currently approved for a liver condition (primary biliary cholangitis) but not specifically for BAD, so its use here remains off-label and limited to patients who have exhausted standard options.

Other FXR agonists are in development for various gastrointestinal and liver disorders, and their effects on bile acid production could eventually benefit BAD patients as well. Animal research has also suggested a possible role for vitamin A in modulating the bile acid feedback pathway, though human data on this front is still lacking.²¹

The Gut Microbiome Angle

Research is revealing that the bacteria living in your colon play a meaningful role in BAD. Normally, gut microbes convert primary bile acids (the ones your liver makes) into secondary bile acids through a two-step process. The first step, called deconjugation, is handled by many species across different bacterial groups. The second step requires a more specialized set of bacteria, predominantly from the Firmicutes group, including species like Clostridium scindens and members of the Ruminococcus family.

In patients with BAD, studies have found a reduction in these specialized bacteria, leading to a buildup of primary bile acids in stool and blood.²² Primary bile acids are the ones that most aggressively trigger water secretion and colonic contractions. So the microbial imbalance does not just reflect BAD; it potentially worsens it by leaving the most irritating forms of bile acid intact. Whether correcting this imbalance through probiotics or targeted microbiome therapy could help treat BAD is still speculative, but it is an active area of investigation.

When BAD Overlaps with Other Conditions

Bile acid diarrhea frequently coexists with other gastrointestinal problems, which complicates both diagnosis and treatment. Microscopic colitis is a good example. A study of patients with microscopic colitis found that over half of those tested for bile acid malabsorption came back positive. Interestingly, whether or not a patient tested positive for BAM did not predict how well they responded to bile acid sequestrants.²³ That finding is a reminder that the relationship between bile acids and diarrhea is not always straightforward: sometimes bile acid sequestrants help even when BAM test results are negative, possibly because they modulate other aspects of intestinal function.

Post-cholecystectomy diarrhea is another common overlap scenario. About half of patients experience changes in bowel habits after gallbladder removal, and bile acid levels in the blood (measured by a marker called 7α-HCO) often rise afterward. However, the rise in bile acid production does not always line up with who develops diarrhea, suggesting that factors beyond simple bile acid overload, such as altered gut motility or sensitivity, play a role in some patients.²⁴

Living with Bile Acid Diarrhea

BAD can be severely debilitating. The urgency, unpredictability, and frequency of diarrhea episodes affect work, social life, travel, and sleep.²⁵ Many patients describe planning their entire day around bathroom access. Nighttime diarrhea, which is unusual in typical IBS, is a particularly disruptive feature that should prompt your doctor to consider BAD specifically.

If you have been told you have IBS-D and standard IBS treatments like fiber supplements, antispasmodics, or low-FODMAP diets have not helped much, it is worth explicitly asking your gastroenterologist about bile acid testing. The conversation can be as simple as requesting a fasting C4 blood level or, if available, a SeHCAT scan. A therapeutic trial of cholestyramine or colesevelam is another reasonable path. Given that roughly a quarter to a third of IBS-D patients may actually have BAD, this is not an obscure zebra diagnosis. It is a common condition hiding behind a different label, and the treatment for it works well when you actually get it.

Timing your sequestrant dose matters too. Most gastroenterologists recommend taking the medication before meals, since that is when bile acid release peaks. Some patients do best splitting their dose across meals rather than taking it all at once. Adjusting the dose up or down based on symptom response, with your doctor’s guidance, is typical and expected. And for those who find cholestyramine intolerable, switching to colesevelam tablets rather than abandoning treatment entirely is often the difference between living with uncontrolled symptoms and getting relief.